Could AR games beat the patch? new study tests lazy eye treatment in teens and adults
NCT ID NCT07622576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a special augmented reality (AR) training program can improve vision in people aged 12 to 55 with lazy eye (amblyopia). It compares the AR method to the standard treatment of patching the stronger eye. The goal is to see if the AR approach is safer and more effective at improving visual sharpness and depth perception.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Individuals aged 12 to 55 years (12 ≤ age ≤ 55 years). Written informed consent shall be obtained from participants aged 18 years and above, or their legal guardians for those aged 12 to 17 years. 2. Unilateral amblyopia with the following criteria: the best-corrected visual acuity (BCVA) of the dominant eye ≥ 0.8, and an interocular BCVA difference of two or more lines. Participants shall have confirmed amblyopia with relevant risk factors and no organic ocular diseases. 3. For Individuals with refractive errors: the spherical equivalent (SE) measured via cycloplegic autorefraction or phoropter refraction ≤ -6.00 D. All participants shall have received optical refractive correction for more than 3 months, with stable visual acuity (acuity change \< 1 line) within the latest 2 months. 4. Individuals with orthotropic eye position, including patients with strabismic amblyopia after strabismus correction. The distance manifest deviation measured at 6 m using the prism and alternate cover test shall be within 5 prism diopters (△). 5. Individuals who are willing to enroll in this study and are able to complete the entire trial protocol. Exclusion Criteria: 1. Participants with other organic ocular disorders, including media opacities, nystagmus, eccentric fixation, acute inflammatory conditions such as keratitis, optic neuropathy, including glaucoma, retinal lesions, and cortical visual impairment. 2. Individuals diagnosed with tumors, cardiac diseases, hypertension, or epilepsy. 3. Individuals with implanted electronic devices such as cardiac pacemakers. 4. Individuals presenting with severe ocular inflammation, photophobia, or lacrimation in either eye. 5. Individuals with a history of ocular surgery that affects visual function, excluding congenital cataract extraction combined with intraocular lens implantation, strabismus correction and blepharoptosis repair. 6. Individuals with severe mental disorders or poor treatment adherence. 7. Individuals currently using or planning to use medications that may affect visual function (mydriatic eye drops for refraction examination such as atropine are excluded). 8. Individuals with diplopia or inability to achieve binocular fusion during augmented reality-based amblyopia training. 9. Individuals who received any amblyopia treatments except spectacle lenses within 2 weeks prior to screening. 10. Individuals who enrolled in other clinical drug trials within 3 months or other medical device trials within 1 month before recruitment. 11. Individuals who are unable to attend regular ophthalmological examinations. 12. Individuals deemed ineligible by the investigators.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amblyopia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China 2nd Affiliated Hospital, School of Medicine
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mixed-Reality headset trains eyes to work together in adults with lazy eye
- A new exercise for the eyes: could it restore 3D vision?
- Video games vs eye patches: a new hope for lazy eye?
- Adult lazy eye may be trainable: brain plasticity under the microscope
- Can a gentle brain zap help adults with lazy eye see better?
- Magnetic pulses to the brain may restore vision in adult lazy eye